Day 2: New data on the use of trastuzumab deruxtecan

Day 2 at the San Antonio Breast Cancer Symposium (SABCS) 2022 focused on new data on the use of trastuzumab deruxtecan.

The updated survival results of the DESTINY-Breast03 study were presented, as well as outcomes of trastuzumab deruxtecan in patients with HER2+ unresectable and/or metastatic breast cancer previously treated with trastuzumab (DESTINY-Breast02 study). Neoadjuvant trastuzumab deruxtecan for early stage breast cancer was discussed in the TRIO-US B-12 TALENT trial.

Prof François Duhoux from the Universités Catholiques Saint-Luc, Brussels, put all these new data in the proper perspective.